text_1: Upon developing tyrosine-kinase inhibitor resistance, new mutations in epidermal growth factor receptors emerge and cause treatment failure.
text_2: Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.